ACCESO CUIDADO

PPTA supports patient access to all medically appropriate plasma protein therapies, which because of important clinical and manufacturing differences, an individual patient may tolerate or respond to one therapy better than another in the same class.

PPTA prepares policy documents (such as issue briefs, statements, backgrounds, and white papers) on a variety of policy topics that are relevant to protecting patient access and are important to the association and its members.

Recently introduced Ontario Bill 178 proposes a ban on compensated plasma donation. This webpage contains PPTA's response to the bill and relevant information.

The European plasma protein industry is a critical provider of lifesaving therapies for patients affected by chronic, life-threatening and debilitating conditions.